Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease

Zachary Junga; Brett Theeler; Manish Singla

doi:10.14309/crj.2018.48

Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease

Zachary Junga, Brett Theeler, Manish Singla

Research output: Contribution to journal › Article › peer-review

Abstract

Infliximab is an anti-tumor necrosis factor α (TNFα) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.

Original language	English
Pages (from-to)	e48
Journal	ACG case reports journal
Volume	5
DOIs	https://doi.org/10.14309/crj.2018.48
State	Published - 2018
Externally published	Yes

Access to Document

10.14309/crj.2018.48

Cite this

@article{5fce0835a0b94ffcb0a08b433499d40b,

title = "Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease",

abstract = "Infliximab is an anti-tumor necrosis factor α (TNFα) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.",

author = "Zachary Junga and Brett Theeler and Manish Singla",

year = "2018",

doi = "10.14309/crj.2018.48",

language = "English",

volume = "5",

pages = "e48",

journal = "ACG case reports journal",

issn = "2326-3253",

}

TY - JOUR

T1 - Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease

AU - Junga, Zachary

AU - Theeler, Brett

AU - Singla, Manish

PY - 2018

Y1 - 2018

N2 - Infliximab is an anti-tumor necrosis factor α (TNFα) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.

AB - Infliximab is an anti-tumor necrosis factor α (TNFα) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.

U2 - 10.14309/crj.2018.48

DO - 10.14309/crj.2018.48

M3 - Article

C2 - 29951563

SN - 2326-3253

VL - 5

SP - e48

JO - ACG case reports journal

JF - ACG case reports journal

ER -